The Master in Logic at the University of Gothenburg offers a variety of courses with a core focus on Mathematical Logic, providing a solid foundation for the study of Logic. Additional courses in ...

Editas Medicine Inc. (NASDAQ:EDIT) is one of the best performing penny stocks to buy now. On September 5, HC Wainwright reiterated a “Buy” rating on the stock and a $5 price target. The positive ...

Imagine that you have a song file—drums, guitar, bass, vocals, piano—and you want to rebalance it, bringing the voice down just a touch in the mix. Or you want to turn a Lyle Lovett country-rock jam ...

Abstract: We propose a model of the substructural logic of Bunched Implications (BI) that is suitable for reasoning about quantum states. In our model, the separating conjunction of BI describes ...

Most developmental psychologists agree that what differentiates leaders is not so much their philosophy of leadership, their personality, or their style of management. Rather, it’s their internal ...

A new study has found evidence of big gains in students’ reading ability from using one specific phonics program—and suggests that consistent implementation is key to getting the strongest results.

Though obstruction-free progress property is weaker than other non-blocking properties including lock-freedom and wait-freedom, it has advantages that have led to the use of obstruction-free ...

A program logic maps visually what will be done (activity), with what resources (inputs), producing what outputs towards progressional outcomes (short, medium and long term outcomes). Essentially it ...

Update (10:35 AM): Adds analysts views. Editas Medicine (NASDAQ:EDIT) plans to slash around 180 jobs, or approximately 65% of its workforce, over the next six months as it transitions towards becoming ...

Metro journalists select and curate the products that feature on our site. If you make a purchase via links on this page we will earn commission – learn more Love Dermalogica skincare or know somebody ...

Shares of Editas Medicine EDIT plunged 12.5% on Tuesday after announcing that it is seeking a global partner to advance its lead gene editing therapy, reni-cel, which is being developed for certain ...